Pathophysiology of parkinsonism due to hydrocephalus


We report a patient with hydrocephalus who developed levodopa responsive parkinsonism and severe bradyphrenia associated with shunt malfunction and revision. Magnetic resonance imaging revealed periaqueductal edema involving medial substantia nigra. [18F]dopa positron emission tomography demonstrated reduced uptake in the caudate and putamen with relative sparing of the posterior putamen. Hydrocephalus associated with shunt malfunction can cause a distinct parkinsonian syndrome with greater dysfunction of projections from the medial substantia nigra to anterior striatum than in idiopathic Parkinson’s disease.

Communicating and non-communicating hydrocephalus can produce parkinsonism that may be relieved with ventricular shunt placement. Clinical features include bradykinesia, rest and postural tremor, loss of postural reflexes, rigidity, and bradyphrenia. Signs of dorsal midbrain impairment such as lid retraction, convergence-retraction nystagmus, light-near dissociation, and forced downgaze may be present. These atypical features suggest that parkinsonism due to hydrocephalus is pathophysiological distinct from Parkinson’s disease (PD). Physical factors such as increased ventricular pressure near the upper midbrain and diencephalon may cause shear, torsion, and ischaemia of projections to the striatum or direct involvement of the striatum. We used magnetic resonance imaging (MRI) and 6-[18F]fluorodopa ([18F]dopa) positron emission tomography (PET) to investigate the pathophysiology of parkinsonism associated with hydrocephalus and shunt malfunction.

PATIENT AND METHODS

Patient
This patient was a 44 year old right handed man who presented at age 26 with personality change and headaches and was diagnosed as having hydrocephalus due to aseptic meningitis. The placement of a ventriculoperitoneal shunt alleviated his symptoms. At age 43 he developed headaches, episodic confusion, and lethargy that were improved by shunt revision.

One month prior to admission, he developed headaches, personality change, and disorientation. Ventricular catheter revision provided modest improvement in symptoms. Within 10 days, he developed persistent downward gaze, headaches, bradykinesia, and reduced speech production. Head computed tomography (CT) showed stable ventricular size. Radiographic visualisation of the shunt hardware showed no disconnection, and he was transferred to our institution for further management.

Examination revealed markedly slow response time and paucity of spontaneous speech. He was completely oriented. He perseverated and provided one word answers. His voice was severely hypophonic and nasal. He had lid retraction and convergence-retraction nystagmus but no light-near dissociation. He had slightly asymmetric rigidity and bradykinesia, severe akinesia, and 3 Hz rest/action tremor in both hands. He had severe postural instability and was unable to walk unassisted. Plantar reflexes were extensor. Unified Parkinson’s Disease Rating Scale motor subscale 3 (UPDRS 3), was 100 out of a possible 108 (on no PD medications).

Ventricular shunt opening pressure was zero. Cerebrospinal fluid studies were normal. A radionuclide study confirmed shunt function.

Levodopa/carbidopa (1500 mg/375 mg per day) markedly improved verbal response time, bradykinesia, and rigidity. With treatment he walked independently but had residual postural instability. No quantitative measures of verbal response time were collected but response times improved from several minutes prior to treatment to seconds after treatment. With treatment and when “on”, UPDRS 3 score was 6.5/108. To investigate the pathophysiology of his parkinsonism, a 3 tesla MRI and [18F]dopa PET scan were performed.

Methods
These studies were approved by the Human Studies Committee and the Radioactive Drug Research Committee of Washington University School of Medicine. All participants gave written informed consent.

[18F]dopa PET studies
[18F]dopa PET scans were performed in the subject (age 44) and in 12 age matched controls (six women, six men; mean age 45 (SD 3.7) years) with typical idiopathic PD. The PD controls had disease duration of 2 (SD 1.1) years and UPDRS3 mean 18 (SD 7) (off medications). We also did [18F]dopa PET studies on 11 normal control subjects (four men, seven women; mean age 49 (11) years) who had normal neurological exams. The subjects were prepared and PET scans were collected, reconstructed, and aligned as previously described. A Siemens 953b in 3D mode was used for all PET studies. Reconstructed resolution of the images was about 6 mm FWHM in the transverse plane.

1.5-T MRI
Each subject had a 3-D MPRAGE MRI with a Siemens Magnetom Vision 1.5 T scanner. A reviewer blinded to the subjects’ clinical status outlined the entire caudate, anterior and posterior putamen, and an occipital region on each side of the brain.

The MPRAGE image was co-registered to the [18F]dopa PET image using AIR and this transformation matrix was used to resample the MR identified regions of interest in the PET image. Decay corrected regional tissue activity PET measurements were extracted from the dynamic series of PET scans.

Abbreviations: [18F]dopa PET, 6-[18F]fluorodopa positron emission tomography; MRI, magnetic resonance imaging; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale
images, and an influx constant (Ki) was calculated with the occipital region as the input using data from 24 minutes to 94 minutes after injection.3

3-T MRI
To delineate the periaqueductal structures, the subjects underwent a Siemens Allegra 3.0-T MRI scan to obtain turbo spin echo (repetition time (TR) = 7000 ms; echo time (TE) = 96 ms) and fluid attenuated inversion recovery (FLAIR; coronal acquisition: TR = 7000, TE = 110, inversion time (TI) = 2100) images.

RESULTS
[18F]dopa PET uptake in our patient was reduced in both the caudate and putamen relatively similarly, which was different from typical idiopathic PD controls (table 1). Although the absolute reduction in the caudate and putamen in our patient was similar to that in the typical idiopathic PD controls, we found that the ratio of caudate to posterior putamen Ki for [18F]dopa in our patient was below the range found in the idiopathic PD controls (see table 1). The 3-T MRI demonstrated increased signal in the region of the ventricular system and the surrounding brain structures on the TSE image (fig 1A, B). No PD control had increased signal in this region.

DISCUSSION
In idiopathic PD, there is a characteristic pattern of dopamine cell loss in the substantia nigra with more lateral areas affected earlier and less degeneration of more medial regions. These lateral neurones preferentially project to the posterior putamen explaining the preferential loss of [18F]dopa uptake in the posterior putamen in PD. This may explain the apparent motor manifestations early in the disease since the posterior putamen more than anterior striatal regions affects motor control. Our patient shares many features with idiopathic PD including the motor manifestations and dramatic response to levodopa. The reduced uptake of [18F]dopa in the putamen is consistent with these clinical observations. Although we cannot prove that our patient’s parkinsonism was due to the hydrocephalus or shunt revision, the abrupt onset, atypical features, and function in the caudate as compared with the average person with idiopathic PD. Our data demonstrate that the caudate to putamen ratio was below the range that we found in PD. However, the difference in the rate of loss in our patient and PD is speculation based upon the abrupt development of clinical manifestations since we have no longitudinal neuroimaging data. Nevertheless, the rate of loss may be an important factor in the severity of this patient’s clinical manifestations despite the relatively modest defects on [18F]dopa PET.

Neuroimaging studies provide important clues to the pathophysiology of our patient’s condition. The reduced uptake of [18F]dopa throughout the striatum indicates either direct impairment of the striatum (perhaps from the effects of enlarged lateral ventricles), interruption of the nigrostrial pathways or dysfunction of the substantia nigra pars compacta. These findings are consistent with single photon emission computed tomography (SPECT) studies that demonstrate reduced cerebral blood flow in both the caudate and putamen; however, the resolution of SPECT is not as good as PET and [18F]dopa is a more direct measure of basal ganglia function. Hydrocephalus could directly impair caudate since the caudate nuclei sit adjacent to the lateral ventricles, but this would not explain putaminal dysfunction. The FLAIR MRI provides an important clue to the site of pathology. Markedly increased signal in the dorsal and ventral medial midbrain suggests that there could be preferential dysfunction of the medial aspects of the substantia nigra pars compacta. This abnormality could be due to direct pressure from the hydrocephalus or shear forces from shunt revision with subsequent changes in ventricular pressure in that area. Although not directly visualised, it is possible that these same forces produce mechanical disruption of nigrostriatal projections including those fibres from

| Table 1 [18F]dopa influx constants (Ki)∗ in the patient and the controls with Parkinson’s disease (PD) |
|---|---|---|---|---|---|---|---|---|
| | Caudate | Anterior putamen | Posterior putamen | Caudate/posterior putamen ratio |
| | Left | Right | Left | Right | Left | Right | Left | Right |
| Patient | 0.0072 | 0.0066 | 0.0082 | 0.0073 | 0.0052 | 0.0056 | 1.27 |
| PD controls | 0.0069 (0.0016) | 0.0068 (0.0014) | 0.0057 (0.0023) | 0.0064 (0.0020) | 0.0035 (0.0018) | 0.0039 (0.0017) | 2.11 (0.85) |
| normals | 0.010 (0.001) | 0.010 (0.002) | 0.012 (0.002) | 0.012 (0.001) | 0.012 (0.002) | 0.012 (0.002) | 0.84 (0.74) |

∗ All values are mean (SD).
† Range.
the medial substantia nigra. The increased signal on FLAIR may indicate residual (or new) edema that may explain the lack of symptom resolution with shunt revision. Direct dorsal midbrain impairment of medial structures including the posterior commissure and rostral interstitial nucleus of the medial longitudinal fasciculus due to the shunt revision likely produced his eye movement abnormalities. Failure of the parkinsonism to resolve with shunt revision might have been due to intermittent shunt dysfunction not detected with one time measurement of shunt pressure. Alternatively, there might be a critical duration of shunt malfunction that leads to irreversible brain injury. Although parkinsonism due to non-communicating hydrocephalus has been well described, this report provides possible anatomical and pathophysiological clues to this illness.

ACKNOWLEDGEMENTS

We thank Dr Steve Lee for help with the patient.

Authors’ affiliations

B A Racette, G J Esper, J Antenor, K J Black, A Burkey, T O Vdeen, V Katagal, J S Perlmutter, Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St Louis, MO, USA
B A Racette, K J Black, J S Perlmutter, American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine, St Louis, MO, USA
B A Racette, K J Black, J S Perlmutter, Huntington Disease Society of America Center of Excellence, Washington University School of Medicine, St Louis, MO, USA
K J Black, S M Moerlein, J S Perlmutter, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA
J G Ojemann, J S Perlmutter, Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO, USA
J G Ojemann, J S Perlmutter, Department of Neurology and Neurosurgical Surgery (Neurosurgery), Washington University School of Medicine, St Louis, MO, USA

This work was supported by NIH grants K23NS43351, NS41509, the Greater St. Louis Chapter of the American Parkinson Disease Association, the Barnes-Jewish Hospital Foundation (The Jack Buck Fund), the Sam & Barbara Murphy Fund, the Elliot H Stein Family Fund and a donation from Ruth Kopelow.

Competing interests: none declared

Correspondence to: Dr B A Racette, Washington University School of Medicine, 660 South Euclid Ave, Box 8111, St. Louis, MO 63110; racetteb@neuro.wustl.edu

Received 16 September 2003
In revised form 6 February 2004
Accepted 20 February 2004

REFERENCES
